All News

Being there for someone who is in need does more than you think.

“When people see me, they just feel like they have to start jogging,” as one chief nurse practitioner tells CURE when discussing how patients with MPNs can reduce their risk of cardiovascular and thrombotic events.

In this on-demand webinar series, CURE partnered with TOUCH, The Black Breast Cancer Alliance to discuss ways patients can be empowered to receive the best care possible.

this on-demand webinar series, CURE partnered with TOUCH, The Black Breast Cancer Alliance to negate common clinical trial misperceptions.

In this on-demand webinar series, CURE partnered with TOUCH, The Black Breast Cancer Alliance to discuss how women of color with breast cancer can learn more about their disease.

In this on-demand webinar series, CURE partnered with TOUCH, The Black Breast Cancer Alliance to discuss low clinical trial participation in Black patients with breast cancer, and factors that may be contributing.

In this on-demand webinar series, CURE partnered with TOUCH, The Black Breast Cancer Alliance to discuss racial disparities in breast cancer.

Researchers found that non-White patients with gastrointestinal cancers, particularly those living in areas with persistent poverty, face inequities in access to and dosage of opioids for end-of-life pain relief.

Patients with cancer and diabetes need to carefully co-manage both diseases, as one expert tells CURE.

Patients with intermediate- or poor-risk clear-cell metastatic renal cell carcinoma saw improved response rates with Opdivo with or without Yervoy.

Two decades ago, I received a stage 4 lymphoma diagnosis, and since then, I’ve learned that life goes on — even with cancer.

The Food and Drug Administration approved a Keytruda regimen to be administered before and after surgery for patients with stage 2, 3A or 3B non-small cell lung cancer.

The FDA will speed up its review of Tagrisso plus chemotherapy for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer after the regimen led to improved outcomes in a phase 3 trial.

One expert explained how patients with breast cancer have an increased risk for blood clots, even though one recently published survey determined that not many patients are aware of this.

Somehow, despite our best intentions and efforts, life throws us curveballs.

A childhood cancer specialist discusses how oncology drug shortages may affect the treatment of children with cancer.

The FDA approved Opdivo for the treatment of patients aged 12 years and older with stage 2B or 2C melanoma that has been surgically removed

The brain cancer vaccine SurVaxM is among the novel treatments currently being studied for patients with glioblastoma.

Suzanne Somers, who was known for her role on “Three’s Company,” died the day before her 77th birthday.

The Food and Drug Administration will speed up the review of odronextamab for patients with relasped or refractory follicular lymphoma or diffuse large B-cell lymphoma.

People-watching is one of my favorite activities.

Interim findings from the phase 2 ASPEN-06 clinical trial show evorpacept’s potential for treatment of patients with HER2-positive gastric/gastroesophageal junction cancer.

Tislelizumab demonstrated similar overall survival and safety in unresectable hepatocellular carcinoma compared with Nexavar, research found.

We’ve all heard the jokes about hospital food.

A new phase 1 trial is testing their first patients with STAR-LLD in the treatment of patients with multiple myeloma.

Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed.

Adding debulking surgery to chemotherapy did not cause a significant decrease in health-related quality of life for patients with metastatic colorectal cancer, research showed.

Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.